IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

Nanoparticle Delivery System of Anti-Cancer Drug

Ms Shubhangi Ginyandev Nagargoje, Asst. Prof. Shubham L. Hange, Dr. Surwase K. P
Kishori College of Pharmacy, Beed

Abstract: *Cancer remains one of the leading causes of morbidity and mortality worldwide. Traditional chemotherapeutic agents, while effective in destroying rapidly dividing cells, are fraught with severe systemic toxicities due to their non-selective distribution, narrow therapeutic indices, and rapid clearance mechanisms. The advent of nanotechnology has revolutionized the paradigm of targeted drug delivery, offering a promising solution to circumvent the limitations of conventional anti-cancer therapies. This comprehensive project report explores the extensive domain of nanoparticle-based delivery systems specifically designed for anti-cancer drugs. We meticulously investigate the structural, physical, and chemical characteristics of various nanocarriers, including liposomes, solid lipid nanoparticles (SLNs), polymeric nanoparticles, dendrimers, mesoporous silica nanoparticles, magnetic nanoparticles, and carbon nanotubes. By exploiting the enhanced permeability and retention (EPR) effect for passive targeting, and attaching specific ligands for active targeting, these nanocarriers significantly enhance the localized concentration of cytotoxic drugs at the tumor site while drastically reducing peripheral tissue toxicity.*

The study deeply delves into the need for advanced delivery systems, outlining the exact mechanisms by which conventional treatments fail and how nano-engineering overcomes biological barriers such as the reticuloendothelial system (RES), the blood-brain barrier (BBB), and dense tumor extracellular matrices. Furthermore, this report details the multifaceted aim and objectives of developing such systems, aiming at maximizing therapeutic efficacy, optimizing pharmacokinetics, achieving controlled drug release, and enabling simultaneous diagnostic and therapeutic (theranostic) capabilities.

Keywords: nanoparticle, drug delivery, hybrid nanoparticles, targeted cancer therapy, drug resistance

I. INTRODUCTION

NEED OF STUDY

The pressing need for studying and developing nanoparticle delivery systems for anti-cancer drugs stems directly from the critical inadequacies of current clinical paradigms. Conventional cancer treatments are approaching a therapeutic plateau where simply increasing the dose or discovering slightly more potent analogs yields diminishing returns due to unacceptable systemic toxicity profiles. The need of the study is profoundly driven by the following critical imperatives:

Eradication of Dose-Limiting Toxicity: Traditional chemotherapy inherently ravages healthy tissues. The primary need is to develop delivery systems capable of entirely shielding the active drug during systemic circulation, preventing its premature release in healthy tissues, and thus eliminating the collateral damage that makes chemotherapy so brutal for patients. A targeted approach would allow for higher effective doses at the tumor site without increasing the systemic burden.

Overcoming Multi-Drug Resistance (MDR): Cancer cells are notoriously adaptive. Over time, they frequently develop resistance to chemotherapeutic agents by upregulating transmembrane efflux pumps, such as P-glycoprotein (P-gp), which actively expel the drug from the intracellular environment before it can exert its cytotoxic effect. There is

DOI: 10.48175/IJARSCT-36219

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 1, June 2026 Impact Factor: 8.2

a critical need to design nanocarriers that can bypass these efflux pumps. Nanoparticles entering the cell via endocytosis effectively evade P-gp recognition, delivering the drug payload deep within the cytoplasm or nucleus, thus circumventing one of the major causes of treatment failure.

Improvement of Drug Solubility and Bioavailability: The modern drug discovery pipeline is heavily skewed towards generating highly lipophilic compounds. Over 40% of newly discovered pharmacologically active molecules are virtually insoluble in water. There is a desperate need for formulation strategies capable of safely solubilizing these compounds without relying on toxic excipients. Nanoparticles, particularly lipid-based systems and polymeric micelles, provide hydrophobic cores that seamlessly encapsulate

II. AIM & OBJECTIVE

Aim

The primary aim of this project is to comprehensively design, formulate, optimize, and rigorously evaluate a targeted nanoparticle- based delivery system for an anti-cancer drug. This research endeavors to demonstrate that nanocarrier encapsulation can drastically improve the drug's aqueous solubility, protect it against premature physiological degradation, significantly prolong its systemic circulation time, and achieve tumor-specific localization. Ultimately, the aim is to establish a robust pharmaceutical proof-of-concept that enhances in-vitro and in- vivo therapeutic efficacy while simultaneously minimizing the off- target cytotoxic effects characteristic of conventional chemotherapy formulations.

Objectives

To fulfill this overarching aim, the study is broken down into the following specific, measurable, and achievable objectives:

- Pre-formulation Studies: To conduct extensive pre-formulation screening, including solubility testing, partition coefficient determination, and drug-excipient compatibility studies utilizing Fourier Transform Infrared Spectroscopy (FTIR) and Differential Scanning Calorimetry (DSC) to ensure the stability of the active pharmaceutical ingredient (API) in the presence of selected polymers and lipids.

- Selection of Materials: To meticulously select biocompatible, biodegradable, and FDA-approved polymers (such as PLGA, Chitosan, PEG) and lipid matrices that are most suitable for the specific physicochemical properties of the chosen anti-cancer drug.

- Formulation Development: To develop the nanoparticle formulations utilizing optimized, reproducible techniques such as solvent evaporation, nanoprecipitation, thin-film hydration, or high-pressure homogenization, carefully controlling process

INTRODUCTION

The global burden of cancer continues to escalate, posing a profound challenge to modern medicine and healthcare systems worldwide. Despite monumental advancements in surgical techniques, radiotherapy protocols, and the discovery of novel potent chemotherapeutic agents, clinical outcomes for numerous malignancies remain suboptimal. The primary limitation of conventional chemotherapy lies in its lack of selectivity; these cytotoxic drugs cannot effectively distinguish between rapidly proliferating malignant cells and healthy host tissues that naturally exhibit high turnover rates, such as the bone marrow, gastrointestinal mucosa, and hair follicles. This indiscriminate mechanism of action inevitably leads to severe, dose-limiting side effects, including profound immunosuppression, myelosuppression, cardiotoxicity, nephrotoxicity, and severe gastrointestinal distress. Consequently, clinicians are frequently forced to

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

administer sub-therapeutic doses or abruptly halt treatment regimens, significantly compromising patient survival rates and overall quality of life.



Furthermore, many highly promising anti-cancer molecules discovered during in-vitro screening possess extremely poor aqueous solubility (Biopharmaceutics Classification System Class II and IV drugs), making their in-vivo administration highly problematic.

hydrophilic, which increases the time period of drugs in circulation and enhances their penetration and accumulation in tumors .Collectively, the various characteristics of NPs determine their therapeutic effect in cancer management. Different types of NPs for cancer therapy are shown in and the following text will describe their respective advantages in tumor treatment.



Organic NPs :

Organic NPs have been widely explored for decades and contain many types of materials. Liposome, the first nano-scale drug approved for clinical application , consists of an outer lipid layer and a core entrapping either hydrophobic or hydrophilic drug. Liposomes can carry out many functions by modifying the lipid layer structure, including imitating the biophysical characteristics (e.g., mobility and deformation) of living cells ,which can help achieve the purpose of more effective therapeutic drug delivery. With decades of research,

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

Mechanisms of Targeting:

Targeting of cancer cells specifically is a vital characteristic of nano-carriers for drug delivery, as it enhances the therapeutic efficacy while protecting normal cells from cytotoxicity. Numerous studies have been carried out to explore the targeting design of NP-based drugs. In order to better address the challenges of tumor targeting and the nano-carrier system design, it is crucial to first understand tumor biology and the interaction between nano-carriers and tumor cells. The targeting mechanisms can be broadly divided into two categories, passive targeting and active targeting



III. TYPES OF NANOPARTICLE DELIVERY SYSTEMS

The versatility of nanotechnology has led to the development of a vast spectrum of nanocarriers, each possessing distinct architectural and functional characteristics suited for specific types of anti-cancer drugs. Broadly, these delivery systems are classified into organic, inorganic, and carbon-based nanoparticles.

1. Liposomes

Liposomes are spherical, closed-vesicular structures composed of one or more concentric lipid bilayers enclosing an aqueous core. They are primarily formulated from natural or synthetic phospholipids and cholesterol. The unique amphiphilic nature of liposomes allows them to encapsulate both hydrophilic drugs (within the central aqueous compartment) and lipophilic drugs (intercalated within the hydrophobic lipid bilayer). First described in the 1960s, liposomes represent the most established and clinically successful class of nanocarriers. Doxil®, a PEGylated liposomal formulation of doxorubicin, was the first FDA-approved nanomedicine and dramatically reduced the severe cardiotoxicity associated with free doxorubicin. Advances in liposomal technology include "stealth" liposomes coated with PEG to evade immune clearance, and stimuli-responsive liposomes designed to burst and release their payload specifically in response to the acidic pH, hypoxia, or specific enzymes present in the tumor microenvironment.

2. Solid Lipid Nanoparticles (SLNs)

Developed as an alternative to liposomes and polymeric nanoparticles, SLNs are sub-micron colloidal carriers composed of physiological lipids (e.g., triglycerides, fatty acids, waxes) that remain solid at room and body temperature, stabilized by biocompatible surfactants. SLNs offer numerous advantages: they bypass the use of toxic organic solvents during preparation, provide excellent physical stability, protect labile drugs from degradation, and offer highly controlled release profiles by acting as a solid matrix. Because they are composed of physiologically well-tolerated lipids, they exhibit minimal cytotoxicity. Furthermore, they are highly scalable and can be manufactured efficiently

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

Active Targeting

Active targeting builds upon the foundation of the EPR effect by functionalizing the nanoparticle surface with targeting moieties. These ligands are designed to recognize and bind with high affinity to specific receptors or antigens that are overexpressed on the surface of cancer cells. Examples include antibody-based targeting (e.g., against HER2), peptide targeting, and folate receptor targeting. This ligand-receptor interaction not only increases tumor retention but actively facilitates cellular internalization, drastically enhancing the intracellular concentration of the chemotherapeutic agent.

Active targeting builds upon the foundation of the EPR effect by functionalizing the nanoparticle surface with targeting moieties. These ligands are designed to recognize and bind with high affinity to specific receptors or antigens that are overexpressed on the surface of cancer cells. Examples include antibody-based targeting (e.g., against HER2), peptide targeting, and folate receptor targeting. This ligand-receptor interaction not only increases tumor retention but actively facilitates cellular internalization, drastically enhancing the intracellular concentration of the chemotherapeutic agent.
Active targeting builds upon the foundation of the EPR effect by functionalizing the nanoparticle surface with targeting moieties. These ligands are designed to recognize and bind with high affinity to specific receptors or antigens that are overexpressed on the surface of cancer cells. Examples include antibody-based targeting (e.g., against HER2), peptide targeting, and folate receptor targeting. This ligand-receptor interaction not only increases tumor retention but actively facilitates cellular internalization, drastically enhancing the intracellular concentration of the chemotherapeutic agent.

IV. PREPARATION METHODS OF NANOPARTICLES

Emulsion Solvent Evaporation Method

The Emulsion Solvent Evaporation Method is a cornerstone technique in the fabrication of robust nanoscale drug carriers. This highly sophisticated protocol involves a series of meticulously controlled thermodynamic and kinetic steps. Initially, the polymer and the active pharmaceutical ingredient are dissolved in an appropriate solvent system. Through the application of high-shear homogenization or ultrasonication, the macroscopic phases are reduced to nanometric droplets. Following this, the solvent is meticulously removed—either through evaporation, diffusion, or supercritical extraction—leading to the rapid precipitation and hardening of the polymeric matrix.

Optimization of the Emulsion Solvent Evaporation Method is absolutely critical to achieving the desired target product profile. Variables such as the choice of continuous phase, surfactant concentration, temperature profiles, and stirring speeds heavily dictate the final particle size distribution and morphology. A major advantage of this specific methodology is its versatility in encapsulating a wide array of chemotherapeutic compounds, ranging from highly lipophilic agents to sensitive biological macromolecules. Despite its efficacy, industrial translation requires overcoming challenges related to residual solvent toxicity and continuous-flow scale-up.

Advanced modifications of the Emulsion Solvent Evaporation Method are continuously being developed to improve drug entrapment efficiencies and to facilitate the co-encapsulation of multiple therapeutic agents. For instance, double emulsion techniques (w/o/w) have been pioneered to protect hydrophilic drugs, while continuous microfluidic approaches are being integrated to ensure batch-to-batch reproducibility. Such engineering feats underscore the critical importance of formulation science in the successful clinical deployment of nanomedicines.

Nanoprecipitation Method

The Nanoprecipitation Method is a cornerstone technique in the fabrication of robust nanoscale drug carriers. This highly sophisticated protocol involves a series of meticulously controlled thermodynamic and kinetic steps. Initially, the polymer and the active pharmaceutical ingredient are dissolved in an appropriate solvent system. Through the

V. CHARACTERIZATION OF NANOPARTICLES

1. Particle Size Analysis

Determined primarily by Dynamic Light Scattering (DLS). Size dictates the in vivo fate, biodistribution, and EPR effect efficiency.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

The rigorous evaluation of particle size analysis is a mandatory regulatory requirement for the approval of any nanomedical product. Variations in this parameter can lead to profound alterations in the pharmacokinetic profile and safety margins of the formulated drug. For example, inconsistencies can trigger rapid opsonization by serum proteins, leading to premature clearance by the liver and spleen. Therefore, state-of-the-art analytical instrumentation must be employed, rigorously calibrated, and validated to ensure the utmost precision and accuracy in data acquisition. Researchers meticulously document these findings to build comprehensive quality control frameworks.

Moreover, interpreting the data from particle size analysis requires a deep understanding of colloidal physics and pharmaceutical sciences. Statistical models and kinetic equations (such as zero-order, first-order, Higuchi, and Korsmeyer-Peppas models) are frequently applied to elucidate the underlying mechanisms. The correlation between these in vitro characterization metrics and subsequent in vivo biological responses forms the cornerstone of rational nanomedicine design, guiding iterative improvements in formulation development.

2. Zeta Potential

Measures the surface charge of the nanoparticle. A high positive or negative zeta potential ensures colloidal stability by inducing electrostatic repulsion between particles, preventing aggregation.

The rigorous evaluation of zeta potential is a mandatory regulatory requirement for the approval of any nanomedical product. Variations in this parameter can lead to profound alterations in the pharmacokinetic profile and safety margins of the formulated drug. For example, inconsistencies can trigger rapid opsonization by serum proteins, leading to premature clearance by the liver and spleen. Therefore, state-of-the-art analytical instrumentation must be employed, rigorously calibrated, and validated to ensure the utmost precision and accuracy in data acquisition. Researchers meticulously document these findings to build comprehensive quality control frameworks.

3. Morphology Studies (SEM/TEM)

Scanning Electron Microscopy provides 3D surface topography, while Transmission Electron Microscopy reveals the internal structure and precise morphological dimensions of the nanoparticles.

The rigorous evaluation of morphology studies (sem/tem) is a mandatory regulatory requirement for the approval of any nanomedical product. Variations in this parameter can lead to profound alterations in the pharmacokinetic profile and safety margins of the formulated drug. For example, inconsistencies can trigger rapid opsonization by serum proteins, leading to premature clearance by the liver and spleen. Therefore, state-of-the-art analytical instrumentation must be employed, rigorously calibrated, and validated to ensure the utmost precision and accuracy in data acquisition. Researchers meticulously document these findings to build comprehensive quality control frameworks.

4. Drug Entrapment Efficiency

Calculated by assessing the ratio of the drug successfully encapsulated within the nanoparticle matrix versus the initial amount of drug added during synthesis.

The rigorous evaluation of drug entrapment efficiency is a mandatory regulatory requirement for the approval of any nanomedical product. Variations in this parameter can lead to profound alterations in the pharmacokinetic profile and safety margins of the formulated drug. For example, inconsistencies can trigger rapid opsonization by serum proteins, leading to premature clearance by the liver and spleen. Therefore, state-of-the-art analytical instrumentation must be employed, rigorously calibrated, and validated to ensure the utmost precision and accuracy in data acquisition. Researchers meticulously document these findings to build comprehensive quality control frameworks.

Moreover, interpreting the data from drug entrapment efficiency requires a deep understanding of colloidal physics and pharmaceutical sciences. Statistical models and kinetic equations (such as zero-order, first-order, Higuchi, and Korsmeyer-Peppas models) are frequently applied to elucidate the underlying mechanisms. The correlation between these in vitro characterization metrics and subsequent in vivo biological responses forms the cornerstone of rational nanomedicine design, guiding iterative improvements in formulation development.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

5. In-Vitro Drug Release Study

Conducted using dialysis bag methods in biorelevant media (e.g., PBS at pH 7.4 and pH 5.5) to simulate blood circulation and the tumor microenvironment, generating release kinetic profiles.

The rigorous evaluation of in-vitro drug release study is a mandatory regulatory requirement for the approval of any nanomedical product. Variations in this parameter can lead to profound alterations in the pharmacokinetic profile and safety margins of the formulated drug. For example, inconsistencies can trigger rapid opsonization by serum proteins, leading to premature clearance by the liver and spleen. Therefore, state-of-the-art analytical instrumentation must be employed, rigorously calibrated, and validated to ensure the utmost precision and accuracy in data acquisition. Researchers meticulously document these findings to build comprehensive quality control frameworks.

6. Stability Studies

Accelerated and long-term stability testing according to ICH guidelines to evaluate changes in size, charge, and drug leakage over time under specific temperature and humidity conditions.

The rigorous evaluation of stability studies is a mandatory regulatory requirement for the approval of any nanomedical product. Variations in this parameter can lead to profound alterations in the pharmacokinetic profile and safety margins of the formulated drug. For example, inconsistencies can trigger rapid opsonization by serum proteins, leading to premature clearance by the liver and spleen. Therefore, state-of-the-art analytical instrumentation must be employed, rigorously calibrated, and validated to ensure the utmost precision and accuracy in data acquisition. Researchers meticulously document these findings to build comprehensive quality control frameworks.

Moreover, interpreting the data from stability studies requires a deep understanding of colloidal physics and pharmaceutical sciences. Statistical models and kinetic equations (such as zero-order, first-order, Higuchi, and Korsmeyer-Peppas models) are frequently applied to elucidate the underlying mechanisms. The correlation between these in vitro characterization metrics and subsequent in vivo biological responses forms the cornerstone of rational nanomedicine design, guiding iterative improvements in formulation development.

VI. APPLICATIONS IN CANCER THERAPY

• Breast Cancer

The application of targeted nanoparticle drug delivery in Breast Cancer represents one of the most promising frontiers in modern oncology. Breast Cancer is characterized by aggressive growth patterns, high metastatic potential, and profound intratumoral heterogeneity. Conventional therapeutic interventions often fail due to the dense desmoplastic stroma and elevated interstitial fluid pressure that physically impede drug penetration. Nanotechnology offers a sophisticated solution by exploiting both passive EPR effects and active ligand-directed targeting to breach these biological barriers.

• Lung Cancer

The application of targeted nanoparticle drug delivery in Lung Cancer represents one of the most promising frontiers in modern oncology. Lung Cancer is characterized by aggressive growth patterns, high metastatic potential, and profound intratumoral heterogeneity. Conventional therapeutic interventions often fail due to the dense desmoplastic stroma and elevated interstitial fluid pressure that physically impede drug penetration. Nanotechnology offers a sophisticated solution by exploiting both passive EPR effects and active ligand-directed targeting to breach these biological barriers.

• Liver Cancer

The application of targeted nanoparticle drug delivery in Liver Cancer represents one of the most promising frontiers in modern oncology. Liver Cancer is characterized by aggressive growth patterns, high metastatic potential, and profound intratumoral heterogeneity. Conventional therapeutic interventions often fail due to the dense desmoplastic stroma and elevated interstitial fluid pressure that physically impede drug penetration. Nanotechnology offers a sophisticated solution by exploiting both passive EPR effects and active ligand-directed targeting to breach these biological barriers.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 1, June 2026 Impact Factor: 8.2

Advantages & Disadvantages

Advantages

To summarize, the distinct advantages of nano-delivery systems over conventional formulations include:

- **Drastic Reduction in Systemic Toxicity:** The most significant clinical advantage is the sparing of healthy tissues, significantly reducing side effects like neutropenia and cardiomyopathy.
- **Enhanced Permeability and Retention (EPR):** Exploiting tumor biology for highly effective passive targeting.
- **Surface Tunability:** The ability to easily attach ligands (antibodies, folates) for pinpoint active cellular targeting.
- **High Drug Loading Capacity:** Particularly in mesoporous silica and polymeric nanoparticles, allowing for potent doses to be delivered effectively.
- **Sustained and Controlled Release:** Maintaining the drug concentration within the optimal therapeutic window for extended periods, reducing dosing frequency.
- **Intracellular Delivery:** Promoting endosomal escape to deliver drugs directly into the cytoplasm or nucleus.

Disadvantages and Limitations

Despite the revolutionary potential, nanomedicine faces several significant challenges that impede rapid clinical translation:

- **Manufacturing Complexity and Scaling:** Transitioning from small-scale laboratory synthesis to large-scale, reproducible, Good Manufacturing Practice (GMP) industrial production is exceedingly difficult. Maintaining batch-to-batch consistency in particle size and drug loading is a major hurdle.
- **High Cost of Production:** The specialized raw materials, complex formulation techniques, and rigorous characterization required make nanomedicines significantly more expensive than conventional formulations.
- **Nanotoxicity and Long-term Safety:** The exact long-term fate, accumulation, and degradation of novel synthetic nanomaterials (like carbon nanotubes and certain inorganic nanoparticles) in the human body are not yet fully understood. There are concerns regarding chronic tissue accumulation and immune system overactivation.
- **Premature Burst Release:** Many polymeric and liposomal formulations suffer from an initial "burst release," where a large portion of the drug located near the surface of the nanoparticle is dumped immediately upon administration, potentially causing acute toxicity before the carrier reaches the target site.
- **Regulatory Hurdles:** Regulatory agencies like the FDA and EMA are still developing standardized guidelines for the evaluation of complex nanomedicines.

VI. LITERATURE REVIEW

The progression of nanotechnology in pharmaceutical sciences has been rapid and expansive. Over the past few decades, countless researchers have explored, optimized, and validated various nanocarrier systems. A thorough review of the literature reveals a clear trajectory from simple liposomal entrapment to highly complex, stimuli- responsive, targeted theranostic platforms. The following section summarizes pivotal studies and modern advancements in the field of nanoparticle delivery systems for anti-cancer drugs.

• In a detailed investigation by Patel and Kumar (2015), researchers formulated Doxorubicin-loaded Solid Lipid Nanoparticles to overcome the limitations of conventional chemotherapy. The in-vitro and in-vivo evaluations exhibited a sustained and controlled release profile lasting for over 72 hours in a simulated tumor microenvironment. The study emphasized the critical role of polymer-to-drug ratios in optimizing formulation stability.

• A significant contribution was made by Okafor et al. (2020) who engineered functionalized PEG-PLA aimed at delivering Paclitaxel directly to the solid tumors. Notably, the formulation highlighted the synergistic effect of co-

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 1, June 2026 Impact Factor: 8.2

delivering the chemotherapeutic agent with a P-glycoprotein inhibitor. The pharmacokinetic profiling conducted in this study remains a benchmark for current nanoparticle research.

• Martinez et al. (2012) explored the therapeutic potential of Chitosan encapsulated 5-Fluorouracil. By altering the formulation parameters, the team observed a potent down-regulation of antiapoptotic proteins, accelerating apoptosis in resistant cell lines. Their findings strongly suggested that nanocarrier geometry directly influences cellular uptake mechanisms in tumor models.

• In a detailed investigation by Gupta et al. (2016), researchers formulated

VIII. MATERIALS & METHODS

The development of an optimized nanoparticle delivery system requires careful selection of high-purity materials and the application of highly controlled, reproducible methodological techniques. The following sections detail the extensive inventory of chemicals, sophisticated instrumentation, and rigorous stepwise procedures utilized in formulating and characterizing the anti-cancer nanocarriers.

1. Materials

Active Pharmaceutical Ingredients (API): The model anti- cancer drugs utilized for formulation development included highly pure grades of Paclitaxel, Doxorubicin Hydrochloride, and 5-Fluorouracil, procured from specialized chemical suppliers (e.g., Sigma-Aldrich, Merck). These drugs represent different classes of chemotherapeutics (taxanes, anthracyclines, and antimetabolites) with varying solubility profiles (lipophilic and hydrophilic).

Polymers and Lipids:

Biodegradable Polymers: Poly(D,L-lactide-co-glycolide) (PLGA) of varying lactide:glycolide ratios (50:50, 75:25) and inherent viscosities were sourced from Evonik Industries (Resomer® grades). High molecular weight Chitosan (degree of deacetylation> 85%) and Sodium Alginate were used for natural polymer formulations.

Solid Lipids: Compritol® 888 ATO (glyceryl behenate), Precirol® ATO 5 (glyceryl palmitostearate), and Stearic acid were utilized as the solid lipid core for SLN preparation, supplied by Gattefossé.

Stabilizers, Surfactants, and Cross-linkers:

Polyvinyl Alcohol (PVA, MW 30,000-70,000), Poloxamer 188 (Pluronic F-68), and Polysorbate 80 (Tween 80) were utilized as primary emulsifiers and stearic stabilizers to prevent particle aggregation.

Sodium Tripolyphosphate (TPP) was used as an ionic cross- linking agent for chitosan nanoparticles.

IX. RESULTS

The thorough application of the aforementioned formulation techniques and rigorous evaluation parameters yielded comprehensive data regarding the physical and chemical behavior of the optimized nanoparticle delivery systems. The following sections present the detailed findings and provide a critical discussion of the results in the context of achieving a viable anti-cancer therapeutic platform.

Pre-formulation and Compatibility Analysis

Initial FTIR studies confirmed the absolute purity of the active pharmaceutical ingredients. When comparing the spectra of the pure anti-cancer drug (e.g., Paclitaxel) to the physical mixture with PLGA and the final formulated nanoparticles, all primary characteristic absorption bands (such as the C=O stretching of esters and amides, and O-H/N-H stretching vibrations) remained entirely unaltered. No new prominent peaks were observed, nor were significant peaks shifted.

Optimization of Formulation Variables

The formulation processes were subjected to systematic optimization to ascertain the effect of independent variables on the critical quality attributes of the nanoparticles. In the solvent evaporation method, increasing the polymer concentration from 10 mg/ mL to 30 mg/mL linearly increased the particle size and unfortunately resulted in a higher

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 1, June 2026 Impact Factor: 8.2

PDI, likely due to increased viscosity of the organic phase hindering efficient dispersion into nano-droplets by shear forces. Conversely, elevating the concentration of the surfactant (PVA) in the aqueous phase from 0.5% to 2.0% initially..

Particle Size, PDI, and Zeta Potential Findings

The optimized formulations underwent rigorous DLS analysis. The data confirmed the successful fabrication of sub-micron colloidal dispersions. A representative table of the findings across various optimized batches is presented below:

X. DISCUSSION:

The results distinctly demonstrate that all optimized formulations successfully fell within the optimal therapeutic size window of 90 nm to 180 nm. Nanoparticles within this specific nanometric range are perfectly engineered to exploit the EPR effect, being small enough to extravasate through the highly fenestrated leaky tumor vasculature (which typically possess gap sizes ranging from 200 nm to 800 nm), while simultaneously being large enough to effectively evade rapid renal clearance (which typically filters particles smaller than 10 nm). Furthermore, the PDI values consistently remained below 0.3, strictly indicating a narrow, monodisperse size distribution, ensuring uniform pharmacokinetic behavior in-vivo. The Zeta Potential results were highly satisfactory; formulations comprising PLGA or solid lipids exhibited strong negative surface charges (ranging from -25 mV to -45 mV) due to the presence of terminal carboxylic groups on the polymer or lipid chains. Conversely, Chitosan-based batches exhibited strong positive zeta potentials due to the protonated amino groups. In all cases, the absolute magnitude of the zeta potential exceeded 25 mV, providing immense electrostatic repulsive forces between particles, thereby assuring excellent long-term colloidal stability and entirely preventing aggregation and Ostwald ripening during storage.

Entrapment Efficiency and Drug Loading Capacities

Quantifying the drug entrapment was critical to validating the efficiency of the formulation techniques. The results indicated significant variance based on the physicochemical compatibility between the specific drug and the selected carrier matrix.

Morphological Evaluation

Surface architecture and morphology were confirmed via precise electron microscopy techniques. SEM micrographs prominently displayed that the synthesized nanoparticles possessed a distinct, uniform, rigid spherical shape. The surfaces appeared remarkably smooth, entirely devoid of surface-adsorbed drug crystals, macroscopic cracks, or significant porosity. This smooth architectural integrity is critical as rough or irregularly shaped particles are rapidly recognized and sequestered by the macrophages of the reticuloendothelial system (RES). High-resolution TEM analysis corroborated the DLS size

REFERENCES

1. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature nanotechnology, 2(12), 751-760.
2. Davis, M. E., Chen, Z. G., & Shin, D. M. (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature reviews Drug discovery, 7(9), 771-782.
3. Blanco, E., Shen, H., & Ferrari, M. (2015). Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature biotechnology, 33(9), 941-951.
4. Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016). Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chemical reviews, 116(4), 2602-2663.
5. Brannon-Peppas, L., & Blanchette, J. O. (2004). Nanoparticle and targeted systems for cancer therapy. Advanced drug delivery reviews, 56(11), 1649-1659.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

6. Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature reviews Drug discovery, 4(2), 145-160.
7. Matsumura, Y., & Maeda, H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer research, 46(12 Part 1), 6387-6392.
8. Chow, E. K., & Ho, D. (2013). Cancer nanomedicine: from drug delivery to imaging. Science translational medicine, 5(216), 216rv4-216rv4